Alexza Pharmaceuticals Inc. Research and Development Expense
Alexza Pharmaceuticals Inc. reported Research and Development Expense of $2.44 million for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2016-05-13
- Alexza Pharmaceuticals Inc. research and development expense for the quarter ending 2016-03-31 was $2.44M, a 36.24% decline year-over-year.
- Alexza Pharmaceuticals Inc. research and development expense for the quarter ending 2015-03-31 was $3.82M, a 22.17% increase year-over-year.
- Alexza Pharmaceuticals Inc. research and development expense for the quarter ending 2014-12-31 was $3.19M.
- Alexza Pharmaceuticals Inc. research and development expense for the quarter ending 2014-09-30 was $3.39M, a 37.86% decline year-over-year.
- Alexza Pharmaceuticals Inc. research and development expense for fiscal 2015 was $11.72M, a 14.78% decline from fiscal 2014.
- Alexza Pharmaceuticals Inc. research and development expense for fiscal 2014 was $13.75M, a 27.95% decline from fiscal 2013.
- Alexza Pharmaceuticals Inc. research and development expense for fiscal 2013 was $19.08M, a 12.66% decline from fiscal 2012.
- Alexza Pharmaceuticals Inc. research and development expense for fiscal 2012 was $21.85M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2016-03-31 | $2.44M 10-Q · filed 2016-05-13 | |||
| 2015-12-31 | $11.72M 10-K · filed 2016-03-28 | |||
| 2015-03-31 | $3.82M 10-Q · filed 2016-05-13 | $7.02M derived: sum of 2 quarters · filed 2016-05-13 | $10.41M derived: sum of 3 quarters · filed 2016-05-13 | $14.44M derived: sum of 4 quarters · filed 2016-05-13 |
| 2014-12-31 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-28 | $6.59M derived: sum of 2 quarters · filed 2016-03-28 | $10.62M derived: sum of 3 quarters · filed 2016-03-28 | $13.75M 10-K · filed 2016-03-28 |
| 2014-09-30 | $3.39M 10-Q · filed 2014-11-05 | $7.42M derived: sum of 2 quarters · filed 2014-11-05 | $10.55M 10-Q · filed 2014-11-05 | |
| 2014-06-30 | $4.03M 10-Q · filed 2014-08-07 | $7.16M 10-Q · filed 2014-08-07 | ||
| 2014-03-31 | $3.13M 10-Q · filed 2015-05-11 | |||
| 2013-12-31 | $19.08M 10-K · filed 2016-03-28 | |||
| 2013-09-30 | $5.46M 10-Q · filed 2014-11-05 | $10.26M derived: sum of 2 quarters · filed 2014-11-05 | $16.48M 10-Q · filed 2014-11-05 | |
| 2013-06-30 | $4.80M 10-Q · filed 2014-08-07 | $11.02M 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | $6.22M 10-Q · filed 2014-05-05 | |||
| 2012-12-31 | $21.85M 10-K · filed 2015-03-13 |